BioNexus Gene Lab (BGLC) Cash & Equivalents (2018 - 2026)

BioNexus Gene Lab has reported Cash & Equivalents for 9 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 35.98% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 35.98% YoY) and the FY2025 annual result came in at $2.4 million, down 17.44% from the prior year.
• Cash & Equivalents eased to $1.3 million in Q1 2026 per BGLC's latest filing, from $2.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.8 million in Q1 2024 and troughed at $814179.0 in Q2 2025.
• A 5-year average of $2.5 million and a median of $2.1 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 221.75% in 2023, then plunged 79.45% in 2025.
• Over 5 years, Cash & Equivalents stood at $2.1 million in 2022, then surged by 113.21% to $4.5 million in 2023, then plunged by 36.1% to $2.9 million in 2024, then slipped by 17.44% to $2.4 million in 2025, then plunged by 43.88% to $1.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.3 million, $2.4 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.